Current and ongoing clinical development of immunotherapy in B-cell malignanciesROSEN, Steven T.Seminars in oncology. 2002, Vol 29, Num 1, issn 0093-7754, 123 p., SUP2Serial Issue

Rituximab in the treatment of diffuse large B-cell lymphomasCOIFFIER, Bertrand.Seminars in oncology. 2002, Vol 29, Num 1, pp 30-35, issn 0093-7754, SUP2Article

Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphomaWARREN, Thomas L; WEINER, George J.Seminars in oncology. 2002, Vol 29, Num 1, pp 93-97, issn 0093-7754, SUP2Article

Emerging information on the use of rituximab in chronic lymphocytic leukemiaKEATING, Michael J; O'BRIEN, Susan; ALBITAR, Maher et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 70-74, issn 0093-7754, SUP2Article

Advances in classification and therapy of indolent B-cell malignanciesKIPPS, Thomas J.Seminars in oncology. 2002, Vol 29, Num 1, pp 98-104, issn 0093-7754, SUP2Article

Rituximab: Mechanism of action and resistanceMALONEY, David G; SMITH, Barbara; ROSE, Andrea et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 2-9, issn 0093-7754, SUP2Article

Rituximab: Ongoing and future clinical developmentGRILLO-LOPEZ, Antonio J; HEDRICK, Eric; RASHFORD, Michelle et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 105-112, issn 0093-7754, SUP2Article

Rituximab in combination with CHOP or fludarabine in low-grade lymphomaCZUCZMAN, Myron S; FALLON, Alexandra; KLIPPENSTEIN, Donald et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 36-40, issn 0093-7754, SUP2Article

Immunotherapy of non-hodgkin's lymphoma with hLL2 (Epratuzumab, an anti-CD22 monoclonal antibody) and hulD10 (Apolizumab)LEONARD, John P; LINK, Brian K.Seminars in oncology. 2002, Vol 29, Num 1, pp 81-86, issn 0093-7754, SUP2Article

Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiersREED, John C; KITADA, Shinichi; YOUNGSOO KIM et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 10-24, issn 0093-7754, SUP2Article

Conceptual aspects of combining rituximab and Campath-IH in the treatment of chronic lymphocytic leukemiaNABHAN, Chadi; ROSEN, Steven T.Seminars in oncology. 2002, Vol 29, Num 1, pp 75-80, issn 0093-7754, SUP2Article

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaGORDON, Leo I; WITZIG, Thomas E; OLEJNIK, Teresa et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 87-92, issn 0093-7754, SUP2Article

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma : Interim follow-up of a multicenter phase ii trialHAINSWORTH, John D.Seminars in oncology. 2002, Vol 29, Num 1, pp 25-29, issn 0093-7754, SUP2Article

Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneSARRIS, Andreas H; YUNFANG JIANG; TSIMBERIDOU, Apostolia M et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 48-55, issn 0093-7754, SUP2Article

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaMANGEL, Joy; BUCKSTEIN, Rena; PENNELL, Nancy et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 56-69, issn 0093-7754, SUP2Article

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-RWILSON, Wyndham H; GUTIERREZ, Martin; O'CONNOR, Paula et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 41-47, issn 0093-7754, SUP2Article